Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Lymphoma highlights from ASH 2021

Amitkumar Mehta • 22 Dec 2021
ASH 2021
Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Glofitamab Mosunetuzumab
BELINDA ELARA POLARIX TRANSFORM ZUMA-7

Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, comments on his highlights in the field of lymphoma presented at ASH 2021, including the Phase III POLARIX trial (NCT03274492) of polatuzumab vedotin (R-CHP) in diffuse large B-cell lymphoma (DLBCL). Dr Mehta additionally talks on the ZUMA-7 (NCT03391466), TRANSFORM (NCT03575351), BELINDA (NCT03570892), and ELARA (NCT03568461) trials, which all assessed chimeric antigen receptor (CAR) T-cell therapies, as well as bispecific antibodies such as glofitamab and mosunetuzumab. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Amitkumar Mehta

2:42
Interim results of an anti-SIRPα antibody, CC-95251, in R/R NHL
Amitkumar Mehta • 22 Dec 2021
3:21
CITADEL-205: Parsaclisib in R/R MCL
Amitkumar Mehta • 22 Dec 2021
3:00
Preliminary results of lemzoparlimab, an anti-CD47 antibody in R/R NHL
Amitkumar Mehta • 22 Dec 2021
1:33
Lymphoma: highlights at ASH 2020
Amitkumar Mehta • 9 Dec 2020

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals